Sponsors (10)
The bill seeks to speed and broaden access to sunscreen options while improving prevention messaging and reducing animal testing, but it trades off increased regulatory and administrative complexity, potential costs to taxpayers and manufacturers, and some uncertainty about long‑term safety when nontraditional evidence is relied upon.
Young people, parents, and at-risk patients would face fewer skin cancer cases because the bill promotes WHO-recommended sun‑safe practices and directs FDA messaging to emphasize sunscreen as an effective prevention tool.
Consumers (including families, children, and seniors) could gain faster access to new or reformulated OTC sunscreen ingredients because the FDA must consider historical safety data and permit real‑world/alternative evidence pathways to support approvals.
Consumers and animal‑welfare–minded Americans would see reduced reliance on animal testing because the bill requires FDA consideration of specified nonclinical non‑animal tests and public tracking of progress toward alternatives.
Parents, children, seniors, and other consumers may face greater uncertainty about long‑term safety and a higher risk of adverse effects if observational/real‑world evidence or alternative tests substitute for full clinical trials.
Taxpayers, consumers, and small manufacturers could bear higher costs because prevention campaigns, new regulatory processes, and requirements to meet specified new testing standards may increase public spending and manufacturer compliance costs that are passed on to buyers or reduce competition.
FDA and consumers could face inconsistent regulatory outcomes or diverted agency resources because broadly accepting alternative test methods and producing annual reports imposes administrative burdens and may create variability in evidence quality and decisions without strong safeguards.
Based on analysis of 5 sections of legislative text.
Requires FDA to adopt flexible, science-based standards allowing real‑world evidence and non‑animal tests when reviewing OTC sunscreen active ingredients and to report annually on progress.
Introduced June 3, 2025 by John Joyce · Last progress June 3, 2025
Requires the FDA to adopt updated, science-based standards for evaluating over-the-counter sunscreen active ingredients that explicitly allow real-world evidence, observational studies, and specified nonclinical non‑animal test methods as alternatives or supplements to traditional clinical tests. Directs the FDA to issue guidance on nonclinical alternatives within 180 days, to apply the new standards to a pending CARES Act administrative order on sunscreen ingredients, and to send annual public reports to relevant congressional committees on implementation and animal‑testing alternatives.